Peripheral arterial disease: medical therapy, intervention and referral
Takes the presentation (asymptomatic low ABI, intermittent claudication, chronic limb-threatening ischaemia or acute limb ischaemia by Rutherford class) with the ABI, toe-brachial index and ankle and toe pressures. It sets the medical therapy: smoking cessation, high-intensity statin to LDL-C < 55 mg/dL, single antiplatelet (clopidogrel or aspirin) or rivaroxaban 2.5 mg twice daily with aspirin, therapy after endovascular or bypass revascularisation and with an oral anticoagulant, BP, diabetes drugs, supervised exercise and cilostazol. It then says when to revascularise (lifestyle-limiting claudication after 3 months of exercise and medical therapy; CLTI as soon as possible, bypass with good vein or endovascular; emergency for acute limb ischaemia) and when and how urgently to refer to vascular surgery. ESC 2024 beside ACC/AHA 2024.
- Mazzolai L, Teixido-Tura G, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024;45:3538-3700.
- Gornik HL, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the management of lower extremity peripheral artery disease. Circulation 2024;149:e1313-e1410.
- Conte MS, Bradbury AW, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S1-S109.
- Björck M, et al. European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia. Eur J Vasc Endovasc Surg 2020;59:173-218.
- Bonaca MP, et al. Rivaroxaban in peripheral artery disease after revascularization (VOYAGER PAD). N Engl J Med 2020;382:1994-2004.
- Anand SS, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease (COMPASS). Lancet 2018;391:219-229.
- Farber A, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia (BEST-CLI). N Engl J Med 2022;387:2305-2316.